RxSight, Inc.

NasdaqGM RXST

RxSight, Inc. Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending September 30, 2024: USD -0.76

RxSight, Inc. Free Cash Flow Per Share is USD -0.76 for the Trailing 12 Months (TTM) ending September 30, 2024, a 51.15% change year over year. Free cash flow per share is the free cash flow generated per share. Indicates investment potential based on cash flow generation.

RxSight, Inc. Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -1.56, a 23.40% change year over year.
RxSight, Inc. Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -2.04, a 8.49% change year over year.
RxSight, Inc. Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -2.23.

Key data

Date	Free Cash Flow Per Share	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)

NasdaqGM: RXST

RxSight, Inc.

CEO	Dr. Ronald M. Kurtz M.D.
IPO Date	July 30, 2021
Location	United States
Headquarters	100 Columbia
Employees	374
Sector	Consumer Discretionary
Industries Eyewear Cosmetics Pharmaceuticals

Description

RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

Key trends

Past 5 years